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RESEARCH
Activation of NQO1 in NQO1*2 
polymorphic human leukemic HL-60 cells 
by diet-derived sulforaphane
Joseph M. Wu*, Ardalan Oraee, Barbara B. Doonan, John T. Pinto and Tze‑chen Hsieh
Abstract 
Background: The NAD(P)H: quinone oxidoreductase (NQO1) confers protection against semiquinones and also 
elicits oxidative stress. The C609T polymorphism of the NQO1 gene, designated NQO1*2, significantly reduces its 
enzymatic activity due to rapid degradation of protein. Since down regulation of NQO1 mRNA expression correlates 
with increased susceptibility for developing different types of cancers, we investigated the link between leukemia and 
the NQO1*2 genotype by mining a web‑based microarray dataset, ONCOMINE. Phytochemicals prevent DNA damage 
through activation of phase II detoxification enzymes including NQO1. Whether NQO1 expression/activity in leukemia 
cells that carry the labile NQO1*2 genotype can be induced by broccoli‑derived phytochemical sulforaphane (SFN) is 
currently unknown.
Methods and Results: The ONCOMINE query showed that: (1) acute lymphoblastic leukemia and chronic myelog‑
enous leukemia are associated with reduced NQO1 levels, and (2) under‑expressed NQO1 was found in human HL‑60 
leukemia cell line containing the heterozygous NQO1*2 polymorphism. We examined induction of NQO1 activity/
expression by SFN in HL‑60 cells. A dose‑dependent increase in NQO1 level/activity is accompanied by upregulation 
of the transcription factor, Nrf2, following 1–10 μM SFN treatment. Treatment with 25 µM SFN drastically reduced 
NQO1 levels, inhibited cell proliferation, caused sub‑G1 cell arrest, and induced apoptosis, and a decrease in the levels 
of the transcription factor, nuclear factor‑κB (NFκB).
Conclusions: Up to 10 μM of SFN increases NQO1 expression and suppresses HL‑60 cell proliferation 
whereas ≥ 25 μM of SFN induces apoptosis in HL‑60 cells. Further, SFN treatment restores NQO1 activity/levels in 
HL‑60 cells expressing the NQO1*2 genotype.
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Background
Cancer is the second most frequent cause of death world-
wide, with a projected 70 % rise over the next two dec-
ades reaching an estimated 24 million new cancer cases 
per year by 2035 [1, 2]. Genomic instability caused by 
dysregulation of intracellular redox status that gives rise 
to sustained oxidative stress is considered to be a risk fac-
tor for cancer [3, 4]. Quinones, present in the intra- and 
extracellular compartments of almost all tissue types, 
contribute to cellular oxidative stress if they participate 
in one-electron transfer reactions with concomitant for-
mation of highly reactive semiquinones [5]. Accordingly, 
half-reduced quinones can participate in the carcino-
genic process by causing depurination of DNA nucleo-
tide bases [6–8].
NAD(P)H:quinone oxidoreductase (NQO1) catalyzes 
two-electron reduction of quinones [9] to products that 
are readily excreted by conjugation with sulfate or glu-
curonic acid [10, 11]. Thus, NQO1 provides protection 
against oxidative stress and exhibits versatility as a cyto-
protective enzyme [12, 13]. In addition to conferring cel-
lular protection, NQO1 counteracts DNA damage by 
Open Access
Experimental Hematology & 
Oncology
*Correspondence:  Joseph_Wu@nymc.edu 
Room 147, Department of Biochemistry and Molecular Biology, Basic 
Sciences Building, New York Medical College, 15 Dana Road, Valhalla,  
NY 10595, USA
Page 2 of 9Wu et al. Exp Hematol Oncol  (2016) 5:27 
preventing semiquinone generation caused by exposure 
to certain xenobiotics and carcinogens, in particular, 
benzo[a]pyrene-derived dihydrodiol epoxides and o-qui-
nones derived from oxidized catechols [14–17]. NQO1 
also controls cell proliferation and induction of apoptosis 
by stabilizing the tumor suppressor protein, p53 [18, 19].
Multiple single-nucleotide polymorphisms (SNPs) 
have been reported to cause a dysfunctional NQO1 
gene [20, 21]. One extensively studied and significant 
polymorphic variant is NQO1*2, which is character-
ized by a C609T (rs1800566, Pro187Ser) polymorphism 
of the NQO1 gene [12, 22, 23]. Individuals carrying het-
erozygous or homozygous alleles of this genetic variant 
manifest with the highly unstable NQO1*2 isoform, that 
undergoes enhanced polyubiquitination and proteaso-
mal degradation, resulting in decreased or complete loss 
of NQO1 activity and a consequential increased suscep-
tibility to cancer [24, 25]. The NQO1*2 polymorphism 
has been widely investigated but limited information is 
available on whether the NQO1*2 genotype is associ-
ated with specific types of cancers and whether it can be 
a useful prognostic indicator for efficacy of chemopre-
vention in specific cancer models. In this communica-
tion, we examined microarray data from the Oncomine 
database to investigate the correlation between under-
expression of NQO1 and human leukemia. An appar-
ent association of reduced NQO1 expression was found 
among different types of leukemia specimens compared 
to normal. Previous studies show that extracts of cruci-
ferous vegetables, such as broccoli, contain antioxidant 
phytochemicals that induce Nrf2-regulated cytoprotec-
tive genes including NQO1 and other phase II detoxi-
fication enzymes [26–28]. However, the ability of the 
isothiocyanate SFN to induce NQO1 functionality in 
NQO1*2 cancer cells remains largely unknown. Accord-
ingly, we perform studies to address the following ques-
tions: (1) can the expression level of NQO1 provide a 
surrogate measure for certain cancers and (2) can broc-
coli-derived SFN activate NQO1 expression in NQO1*2 
cells? We provide evidence that SFN [29–31] can induce 
NQO1 enzymatic activity and expression of the NQO1*2 
polymorphic variant. SFN also upregulates a number of 
cytoprotective enzymes involved in maintaining intra-
cellular redox capacity [32, 33].
Methods
Oncomine analyses
The freely available web-based microarray dataset plat-
form, Oncomine [34, 35], was used to examine the fold 
change of NQO1 mRNA expression levels among leuke-
mia samples. The keywords ‘NQO1’, ‘leukemia’, ‘HL-60’ 
and ‘clinical specimen’ were used to obtain the initial data 
for evaluation. A further quality check was conducted 
using p  <  0.01 as the statistical threshold; only samples 
with NQO1 expression data that met this level of signifi-
cance were included in the analyses.
Reagents
Sulforaphane was purchased from LKT Laboratories (St. 
Paul, MO). Bovine serum albumin (BSA), menadione, 
dicoumarol and NADPH were purchased from Sigma-
Aldrich Corporation (St. Louis, MO). Primary antibodies 
against NQO1, Keap1, Nrf2, NFκB p50, NFκB p65, IκB, 
caspase 2, caspase 3, bcl-2, bax, actin, histone H1 and 
secondary antibodies were purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA). Anti-poly (ADP-
ribose) polymerase (PARP) antibody was purchased from 
Biomol International, L.P. (Plymouth Meeting, PA). Fetal 
calf serum, RPMI-1640, penicillin and streptomycin were 
purchased from Cellgro, Inc (Herndon, VA). All other 
chemicals and solvents used were of analytical grade.
Cell culture and growth inhibition assay
Human promyelocytic leukemia cell line (HL-60) was 
obtained from American Type Culture Collection 
(Manassas, VA) and maintained in RPMI-1640 supple-
mented with penicillin, streptomycin and 10 % heat inac-
tivated fetal calf serum, as previously described [36–38]. 
For treatment, cells were seeded at a density of 1 × 105 
cells/ml. SFN dissolved in 1 N NaOH solution and neu-
tralized with HCl, was added to the culture medium to 
final concentrations of 0, 1, 2.5, 5.0, 10, and 25 μM. Cells 
were treated with SFN and harvested at different times 
post-treatment, as indicated in Figs.  1, 2, 3, 4. Cell via-
bility was determined by trypan blue exclusion using a 
hemocytometer. Cell pellets were stored at −80  °C for 
biochemical and molecular analyses.
Preparation of cell extracts for immunoblot analysis
For immunoblotting experiments, cells were lysed in ice-
cold RIPA buffer (50  mM Tris, pH 7.4, 150  mM NaCl, 
1 mM EDTA, 1 % Triton X-100, 1 % deoxycholate, 0.1 % 
SDS, 1 mM dithiothreitol and 10 μl/ml protease inhibitor 
cocktail). Cytosol, mitochondria and nuclear fractions for 
the analysis of subcellular distribution of Keap1 and Nrf2 
were isolated using commercially available kits (Sigma-
Aldrich Corporation, St Louis, MO). Protein concentration 
of cell lysates and fractionated cell extracts were deter-
mined by the Coomassie protein assay kit (Pierce Chemi-
cal Company, Rockford, IL) using BSA as a standard.
Immunoblotting
The cell lysates or extracts prepared from cell fractions 
were resolved by 10 % SDS-PAGE and the proteins were 
transferred to a nitrocellulose membrane and blocked 
overnight at 4  °C in TBST buffer (10  mM Tris, pH 7.5, 
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100 mM NaCl and 0.05 % Tween-20) containing 3 % non-
fat dried milk. The blots were incubated with various 
primary antibodies, followed by incubation for 1 h with 
appropriate secondary antibodies. The expression levels 
of actin and histone H1 were used as loading controls. 
The intensity of the specific immunoreactive bands was 
detected by enhanced chemiluminescence (ECL), quanti-
fied by densitometry and normalized against either actin 
or histone H1, as previously described [38].
Cell cycle analysis
HL-60 cells treated with different concentrations of SFN 
(0, 1, 2.5, 5, 10, and 25  μM) were assayed for changes 
in cell cycle phase distribution using flow cytometry. 
Cells were stained with 1.0  μg/ml DAPI (from Sigma-
Aldrich Corporation, St. Louis, MO) at pH 6.8, as previ-
ously described [38, 39]. DNA content histograms were 
obtained and the percentage of cells in the respective 
phases (G1, S and G2/M) of the cell cycle was quanti-
fied. Cells undergoing apoptosis were estimated using the 
appearance of the sub-G1 peak [38, 39].
Enzyme activity assays
For enzyme activity assays, cells were resuspended in ice-
cold 50  mM potassium phosphate buffer (pH 7.4) con-
taining 2  mM EDTA and sonicated. Subsequently, cell 
suspensions were subjected to centrifugation at 13,000×g 
for 10  min at 4  °C. The resulting supernatant fractions 
were collected for the measurement of enzyme activities 
shown below [40].
NQO1 activity assay
NQO1 activity was measured by the modified method 
of Lind et al. [41]. Briefly, the reaction was started with 
the addition of menadione into the reaction mixture 
containing 33 mM potassium phosphate buffer (pH 7.4), 
0.18 mM NADPH, 0.02 % BSA, 0.01 % Tween-20 and cell 
lysates [40]. The oxidation of NADPH was monitored 
spectrophotometrically at 340 nm, 25  °C for 2 min with 
and without 20  μM dicoumarol. The dicoumarol-sen-
sitive portion of the activity was regarded as a measure 
of NQO1 activity, using the NADPH extinction coeffi-
cient (6.22 mM−1 cm−1) and defined as μmol of NADPH 
oxidized·min−1·mg−1 protein.
Data analysis
The results are expressed as mean ±  standard deviation 
(SD). Differences among groups are assessed by one-way 
analysis of variance using the SPSS software package for 
Windows. Data among control and SFN-treated cells are 
compared using the least significance difference (LSD) 
test; statistical significance at p < 0.001 or < 0.01 is given 
respective symbols in the figures.
Results
Survey NQO1 status using oncomine
The Oncomine database search was performed to exam-
ine the association of NQO1 mRNA expression levels 
across different sub-type leukemia studies using the 
reported p values and fold-changes. In two analyses that 
compared clinical human tissue samples of normal vs 
leukemia patients, under-expressed NQO1 was found in 
human acute lymphoblastic leukemia (ALL) and chronic 
myelogenous leukemia (CML) [42, 43] (Table  1). Since 
rapid proteolysis of NQO1 occurred in the NQO1*2 
isoform [44], low expression of NQO1 found in the 
individuals with ALL and/or CML most likely carry 
heterozygous or homozygous NQO1*2 alleles. Several 
Fig. 1 Effect of SFN on NQO1 protein expression and activity. a West‑
ern blot analysis of NQO1 protein expression in cell lysates treated 
with 0, 1, 2.5, 5, 10 and 25 μM SFN for 24 and 48 h. b NQO1 enzyme 
activity assay in cell lysates treated with 0, 1, 2.5, 5, 10 and 25 μM SFN 
for 24 and 48 h. c Subcellular distribution of Keap 1 and Nrf2 in the 
cytosol, mitochondria and nucleus in control and 48 h, SFN‑treated 
HL‑60 cells. Actin and histone H1 were used as loading controls 
for cytosolic and nuclear fractions, respectively. The intensity of 
specific immunoreactive bands was quantified by densitometry and 
expressed as fold differences against actin. Values of NQO1 enzyme 
activities are mean ± SD for three experiments and activities of NQO1 
are expressed as µmol of NADPH oxidized·min−1
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leukemia cell lines are available and can be used as an 
in  vitro cell model to examine the activation of NQO1 
expression in NQO1*2 cells. Our studies investigated 
HL-60 leukemic cells, since previous PCR–RFLP analy-
sis for the SNP (C609T) demonstrated that these cells 
are heterozygous for the NQO1*2 polymorphism [45]. A 
further search of the oncomine database involving can-
cer cell line panels indicated that NQO1 expression in 
HL-60 cells is consistently low or absent (Table 2). Of 6 
HL-60 cell studies queried in oncomine—four published 
[46–49] and two unpublished (Compendia and Wooster 
studies), low NQO1 expression consistently ranked in the 
top 1–4 % of under-expressed genes [47]; this significant 
reduction in NQO1 can be attributable to the presence of 
genetic polymorphisms on C609T mutation [22, 44, 45, 
50, 51]. Thus, our interrogation of the Oncomine micro-
array dataset platform provides support that HL-60 cells 
can serve as an appropriate experimental model to study 
the activation of NQO1 expression and function by broc-
coli-derived SFN.
Control of NQO1 in NQO1*2 cells by SFN is accompanied 
by concomitant change in Nrf2
HL-60 cells were treated with varying doses of SFN for 
different periods of time. Western blot analysis revealed 
dose-dependent increases in NQO1 protein expression 
with the greatest induction occurring after 24  h with 
5–10  μM SFN and with 1 μM SFN sufficient to more 
than double NQO1 levels after treatment for 24- and 
48-h (Fig. 1a). Whereas, treatment with 25 μM SFN for 
Fig. 2 Effect of SFN on cell proliferation, viability and cell cycle control in HL‑60 cells. a Cells were treated with 0, 10 and 25 μM SFN and the cell 
numbers were determined at 6, 15, 24 and 48 h by counting using a hemocytometer. Cell viability was measured using the trypan blue exclusion 
assay. Values are expressed as mean ± SD for three experiments, and asterisks * and ** shown above bars indicate statistical significance of p < 0.01 
and p < 0.001, respectively, compared to vehicle‑treated control. b, c Cells were treated with 0, 10 and 25 μM SFN for 24 and 48 h and analyzed by 
flow cytometry. The cells in sub‑G1 phase are used to estimate apoptotic cells
Fig. 3 Induction of apoptosis by SFN as determined by changes in 
PARP cleavage, appearance of p‑H2AX, decreases in pro‑caspase 2 
and pro‑caspase 3. Western blot analysis revealed down regulation 
of PARP expression as evidenced by appearance of the 89‑kDa PARP 
cleavage product, induction of p‑H2AX, and down‑regulation of both 
pro‑caspase 2 and pro‑caspase 3 in ≥ 10 μM, 48 h SFN treated cells
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48-h had a significant inhibitory effect on NQO1 pro-
tein expression. These results are reflective of a hor-
metic response and suggest that 1–10 μM SFN is able to 
induce NQO1 levels in HL-60 cells expressing NQO1*2 
genotype.
We next examined whether the observed change in 
NQO1 protein expression correlated with changes in 
NQO1 enzymatic activity. As shown in Fig. 1b, treatment 
with 10 μM SFN for 24- and 48-h revealed time-depend-
ent increases in NQO1 enzyme activity. Conversely, SFN 
treatment at 25 µM for 24- and 48-h resulted in a signifi-
cant inhibitory effect on NQO1 activity which may corre-
late with inhibition of NQO1 protein expression that we 
observed (Fig. 1b). Previous studies show that SFN targets 
the transcription factor, Nrf2, by de-repressing its Keap1-
dependent ubiquitination and enabling stabilization and 
subsequent nuclear translocation of Nrf2 to induce ARE 
detoxification enzymes that includes NQO1 [52]. There-
fore, we next investigated whether changes in NQO1 
activity by SFN are due to alterations in the subcellular dis-
tribution of Keap1-Nrf2 in HL-60 cells. Western blot anal-
ysis data show that SFN treatment for 48 h down-regulates 
cytosolic Keap1 accompanied by increases in nuclear Nrf2 
in a dose-dependent manner (Fig. 1c). These results sug-
gest that SFN enhances cytosol-to-nucleus translocation 
of Nrf2 which partially supports the induction of NQO1 
by SFN via Keap1-Nrf2 changes at 10 μM while the control 
of NQO1 by SFN at 25 μM remains unclear.
Control of HL‑60 proliferation and cell cycle phase 
transition by SFN
In addition to SFN controlling expression and activ-
ity of NQO1 in NQO1*2 HL-60 cells, we also exam-
ined whether SFN affects cell proliferation and viability. 
Trypan blue exclusion assays were performed and results 
showed time-dependent growth inhibition of HL-60 cells 
by SFN after 24- and 48-h with an IC50 of approximately 
10  μM at 48-h post-treatment (Fig.  2a). In addition, 
time- and dose-dependent decreases in cell viability were 
observed following 24- and 48-h treatments with 10 and 
25 μM SFN as compared to control cells (Fig. 2a).
Cell cycle analyses were performed to determine 
whether SFN alters cell cycle distribution. The percent 
of cells in G1, S, and G2 phases was analyzed (Fig.  2b). 
The amount of DNA in sub-G1 phase, indicative of DNA 
fragmentation, was used to estimate cell death. As shown 
in Fig.  2b, SFN treatment for 24  h caused a substantial 
decrease in number of cells in S-phase and a concomi-
tant increase in cells accumulating in sub-G1 phase (1.8 % 
in control vs 34 and 63.5 % in cells treated with 10 and 
25 μM SFN, respectively). Prolonged (48-h) exposure of 
HL-60 cells to 10 and 25 μM SFN resulted in a significant 
decrease of cells in both G1- and S-phases, and an accu-
mulation of cells in sub-G1 phase (Fig. 2c). These results 
suggest that SFN inhibits cell proliferation through cell 
cycle arrest and induces apoptotic cell death.
Fig. 4 Effect of SFN on the changes of NFκB p65, p50, IκB, bcl‑2 and 
bax expression in HL‑60 cells. a Western blot analysis revealed the 
alteration on NFκB subunits p65/p50 and IκB expression in 48 h SFN 
treated cells. b The total protein expression level of bax and bcl‑2 was 
determined by Western blot analysis and the normalized level of cel‑
lular bax and bcl‑2 and alteration in the ratio of bax to bcl‑2 in HL‑60 
cells treated for 48 h with increasing doses of SFN were calculated. 
In a and b, the intensity of the specific immunoreactive bands were 
quantified by densitometry and expressed as a fold difference against 
actin (loading control)
Table 1 Comparison of  NQO1 expression across  2 clinical 
specimens as compared to levels in healthy tissue
The mRNA expression levels of NQO1 were compared in normal vs different 
clinical sub-types of leukemia patients using the reported gene ranks, p values, 
and fold changes. The clinical specimen fold-change is defined as change in 
NQO1 mRNA expression level in the leukemia tissue compared to NQO1 mRNA 
expression level in corresponding normal tissue. Gene rank orders are generated 
based on the p values obtained in differential gene expression analysis. 
The gene expression data retrieved from the Oncomine compendium is log 
transformed and the standard deviation was normalized to one
Under‑expressed NQO1
Cancer type Gene rank (%) p value Fold change Reference
ALL Top 1 8.27E−5 −1.138 Kirschner‑
Schwabe [45]
CML Top 5 1.29E−10 −1.619 Radich [46]
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Control of apoptotic induction and apoptogenic gene 
expression by SFN in HL‑60 cells
Induction of apoptosis by SFN was revealed by the 
appearance of sub-G1 fraction (Fig.  2); biochemical 
analysis on SFN-induced apoptosis was further inves-
tigated by changes in PARP. Dose-dependent decreases 
in PARP expression and the appearance of the distinct 
PARP cleavage product were observed in HL-60 cells 
treated with 25 μM SFN for 48 h (Fig. 3). Corroborative 
evidence of induction of apoptosis by SFN was further 
observed by a dose-dependent induction of p-H2AX, a 
phosphorylated histone which usually marks double-
stranded DNA breaks (Fig. 3a) [53, 54]. In addition, the 
pro-apoptotic potential of SFN was also examined by 
changes in caspase activation. Treatment with SFN for 
48 h decreases pro-caspase 2 as well as pro-caspase 3 
expression, indicative of their conversion to active exe-
cution caspases that are critical to the induction of apop-
tosis (Fig.  3). Taken together, SFN-induced apoptosis 
in HL-60 cells was supported by induction of p-H2AX 
expression, PARP cleavage, and caspase mediated cell 
death.
Control of anti‑apoptotic gene expression by SFN in HL‑60 
cells
A previous study demonstrated that SFN triggers TNF-
á-induced apoptosis through inhibition of NFκB and 
activation of caspase-3 in leukemia cells [55]. We further 
examined the control of NFκB by SFN in HL-60 leuke-
mia cells. Cells were treated with 10 and 25 μM of SFN 
for 48 h and changes on p65/p50 subunits of NFκB and 
its inhibitor (IκB) were determined. SFN significantly 
reduced expression of p50 subunits whereas minimum 
changes in IκB expression were observed (Fig. 4a). Alter-
ing the combination of dimers within NFκB can disrupt 
its transcriptional activity by preventing other transcrip-
tionally active NFκB dimers from binding to κB tran-
scription sites or facilitating recruitment of deacetylases 
to promoter regions [56]. Thus, SFN inhibits NFκB activ-
ity by modifying its heterodimer p65/p50. NFκB regu-
lates the expression of anti-apoptosis proteins including 
bcl-2, and the ratio between bcl-2 and its correspond-
ing apoptosis agonist, bax regulates a biological path-
way responsible for cell death. Accordingly, we further 
examined the expression of bax and bcl-2 in HL-60 cells 
in response to SFN treatment [57]. As shown in Fig. 4b, 
incubation of HL-60 cells with 10  μM SFN for 48  h 
induced bax over-expression. This was accompanied by a 
concomitant decrease of bcl-2 which led to an increase 
in the bax/bcl-2 ratio favoring cell death suggesting that 
induction of apoptosis by SFN is partially through NFκB 
mediated down regulation of bcl-2.
Discussion
SNPs are widely observed in the human population 
and may vary from nonsynonymous to synonymous to 
manifestations occurring in the noncoding region of the 
human genome. SNPs can exert influences on gene pro-
moter activity and hence the transcription of mRNAs as 
well as their conformation and stability. In addition, SNPs 
can alter the subcellular localization of mRNAs and/or 
proteins and hence can manifest clinically as diseases in 
humans. Silencing of genes due to SNPs is also known to 
occur in eukaryotes and mammalian systems.
NQO1 is affected by several common SNPs of which 
the C609T serine-to-proline substitution, known 
as NQO1*2, shows significant correlation with can-
cer susceptibility [20, 24]. Genotyped individuals who 
are homozygous for the NQO1*2 polymorphism have 
silenced NQO1 expression and almost complete loss 
of NQO1 enzymatic activity, while those genotyped as 
heterozygous show reduced levels of NQO1 activity 
and protein expression. Two human hematopoietic cell 
lines, HL-60 (promyelocytic leukemia) and Raji (Burkitt’s 
lymphoma), both show similar, substantial reduction of 
NQO1 transcript levels [45]; phenotypically, however, a 
complete loss of NQO1 activity was only evident in Raji, 
while the HL-60 cells expressed a low level of enzyme 
activity. One interpretation of these discordant findings 
is that while the expression of NQO1 is controlled by a 
transcriptional mechanism in both cell types, in the Raji 
cell line the dominant control may lie in the post-tran-
scriptional proteolytic degradation of NQO1 and that 
this regulatory feature is not shared by HL-60 cells [44]. 
This may be viewed in light of various genetic allele con-
trast models (C vs T), i.e., dominant (CC vs CT + TT), 
Table 2 Comparison of NQO1 expression in HL-60 across 6 
analyses using human cancer cell lines
The mRNA expression levels of NQO1 in the HL-60 cell line were investigated. 
The fold-change is defined as decrease in level of NQO1 mRNA expression 
in the HL-60 or in different leukemia cells compared to expression levels 
in non-leukemic cell lines. Gene rank orders are generated based on the p 
values obtained in differential gene expression analysis. The gene expression 
data retrieved from the oncomine compendium are log transformed and the 
standard deviation were normalized to one
Under‑expressed NQO1
Cell line Gene rank (%) p value Fold change Reference
HL‑60 Top 1 1.76E−98 −3.978 Garnett [48]
HL‑60 Top 2 1.08E−4 −7.291 Compendia (not 
published)
HL‑60 Top 2 1.09E−4 −7.395 Shankavaram [49]
HL‑60 Top 2 1.73E−62 −11.959 Barretina [47]
HL‑60 Top 2 1.47E−17 −4.235 Wooster (not 
published)
HL‑60 Top 4 8.21E−5 −6.637 Lee [50]
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recessive (CC +  CT vs TT), homozygous co-dominant 
(CC vs TT), and heterozygous co-dominant (CC vs CT). 
In particular, the NQO1 609CT + TT genotype is more 
common in ALL patients than in controls. Carriers of 
the variant T allele exhibit a 2.64-fold increased risk for 
cancer development [58]. These results are in agreement 
with previously published studies that report under-
expression of NQO1 in leukemia (specifically, HL-60 
cells) with low NQO1 transcript levels [59, 60]. Thus, 
our studies using HL-60 to test and advance the feasibil-
ity that isothiocyanates in particular SFN can reactivate 
NQO1 gene expression and activity in NQO1*2 cells.
Restoration of NQO1 activity has important impli-
cations not only for cytoprotection of cells but also for 
increasing the sensitivity of cells to chemotherapeutic 
agents such as β-lapachone or mitomycin C. Traditional 
metabolic studies on NQO1 have regarded two-electron 
reductions of quinones to hydroquinones as a detoxi-
fication mechanism because it circumvents formation 
of highly reactive semiquinones. In reality, the chemical 
nature of the quinone and/or hydroquinone will dictate 
whether the effect involves a toxification or a detoxifica-
tion reaction. Two-electron reductions of both synthetic 
and naturally-occurring quinones can induce toxicity in 
cancer cells. Thus, NQO1 can mediate a futile two-elec-
tron cycling between the oxidized quinone forms of the 
aforementioned drugs and their two-electron reduced 
hydroquinone forms to induce tumor cell death [12, 
61]. The bioactivation of a quinone-containing prodrug 
such as mitomycin C by NQO1 can be attenuated or 
nulled in individuals with the heterozygous (CC vs CT) 
or homozygous (TT vs CC) NQO1*2 genotype, respec-
tively [62]. Results of the NQO1 enzyme activity assay, 
in combination with a robust expression of the NQO1 
protein (see western blot Fig. 1a, b), clearly show resto-
ration/induction of NQO1 protein expression and activ-
ity in cancer types expressing low levels of the protein, 
specifically in NQO1*2 (HL-60) cancer cells. Thus, the 
demonstration that low NQO1 expression levels could 
be substantially increased through the use of chemopre-
ventive agents such as SFN, which has much potential for 
implication in anticancer prodrug therapy.
In support of prodrug idea and the potential applica-
tion of NQO1 status as a biomarker for certain can-
cers, we examined microarray data from the Oncomine 
database to further investigate the association between 
NQO1*2 and human cancer. Under-expression of NQO1 
transcription has been observed in virtually all lymphoma 
cancer types. Of note, downregulation of NQO1 was 
found in follicular lymphoma and Burkitt’s lymphoma 
[45] and, in a series of three lymphoma cell lines, under-
expression of NQO1 transcription was shown to corre-
late with decreased sensitivity to the chemotherapeutic 
agents: mitomycin C, fluorouracil, and benzoquinone 
ansamycins e.g. geldanamycin.
Moreover, several instances of substantially dimin-
ished NQO1 levels in human sarcoma samples were 
also observed. Statistically significant under-expression 
of NQO1 was discovered in liposarcoma and soft tissue 
sarcoma. In particular, a difference in NQO1 expression 
was found between cases of liposarcoma with wild-type 
or mutant p53. Specifically, the liposarcoma samples with 
mutant p53 exhibited 3-fold lower levels of NQO1 than 
those with wild-type p53. These results are comparable 
with previously published data which show that mutant 
p53 is associated with diminished levels of NQO1 and 
other phase II detoxification enzymes [63]. As a result 
of the potent tumor suppressive functions of wild-type 
p53, any factor that disrupts p53 stability may attenuate 
wild-type activity and contribute to cell transformation 
and carcinogenesis. This is of prime importance because 
NQO1 stabilizes p53 and prevents its degradation [18, 
64–66].
In summary, the present study supports the emerging 
fields of nutrigenomics and nutrigenetics that describe 
the ability of specific nutrients to activate intracel-
lular signaling pathways. We demonstrate that low 
NQO1 expression, as found in human leukemic HL-60 
cells harboring the polymorphic NQO1*2 variant can 
be reactivated by physiologically achievable doses of 
SFN via a mechanism involving the activation of Nrf2-
mediated transcription signaling control. It is notewor-
thy that in nutrigenomic studies comparing potency 
of phytochemicals, SFN exhibits the highest potency 
determined by its “CD value”, defined as the concentra-
tion of a compound required to double NQO1 specific 
activity in Hepa 1c1c7 murine hepatoma cells [67, 68]. 
The concentration of SFN required to double the activ-
ity of NQO1 is as low as 0.2 μM. Although some stud-
ies indicate that high doses of phytonutrients provide 
the greatest cytoprotective effects, our studies confirm 
the findings of others that lower doses of SFN may have 
greater efficacy [69].
Diets rich in SFN or its precursor may result in bio-
available amounts that are sufficient to overcome the 
“CD” threshold required to reactivate NQO1*2 to expres-
sion levels comparable to that of the NQO1 genotype 
for treatment of patients with leukemia. Characterizing 
responders to neoadjuvant therapy would be particularly 
beneficial in population groups known to have a high 
prevalence of the homozygous NQO1*2 genotype [70]. 
Knowledge of the CD threshold is critical to minimize 
overtreatment by improving efficacy of cancer chemo-
therapy and/or avoid unnecessary delay of treatment in 
alleviating cancer susceptibility. These possibilities war-
rant further research and are under active consideration.
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Conclusions
Important findings addressed are (1) Oncomine mining is 
a valuable and useful approach to guide future research, 
(2) SNP-associated NQO1 levels of expression can serve 
as a biomarker for certain cancers and (3) SFN can acti-
vate NQO1 expression in NQO1*2 cells.
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